Relative CTLA-4, PTPN-22, and interleukin 37 mRNA expressions in patients with lupus nephritis-Reference-Cited by-同舟云学术

Relative CTLA-4, PTPN-22, and interleukin 37 mRNA expressions in patients with lupus nephritis

Published:2023-04 Issue:4 Volume:19 Page:180-187
ISSN:1699-258X
Container-title:Reumatología Clínica
language:en
Short-container-title:Reumatología Clínica

Author:

A. Moneim Nermeen Hassan,Hosny Marwa Mohamed,Omar Hanan Hassan^ORCID,Abdelnaby Mai Mohamed,Fouad Marwa Mohamed,Abd El-Waheed Waleed Omar,Elmedany Samah Hamdy,Zaki Heba Mohamed

Publisher

Elsevier BV

Subject

Rheumatology

Reference30 articles.

1. Taming lupus-a new understanding of pathogenesis is leading to clinical advances;Liu;Nat Med,2012

2. The efficacy of novel B cell biologics as the future of SLE treatment: a review;Kamal;Autoimmun Rev,2014

3. Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus;Pacheco-Lugo;Lupus,2019

4. The potential use of serum interleukin-21 as biomarker for lupus nephritis activity compared to cytokines of the tumor necrosis factor (TNF) family;Shater;Lupus,2022

5. Novel biomarkers for systemic lupus erythematosus;Zeng;Biomark Med,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digital ischemia: a rare immune-related adverse event of immune checkpoint inhibitors—case report and review of the literature;Rheumatology International;2024-09-04

2. Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis;International Journal of Molecular Sciences;2023-10-04

3. Targeting abnormal lipid metabolism of T cells for systemic lupus erythematosus treatment;Biomedicine & Pharmacotherapy;2023-09